

CARBOPLATIN

An option for patients with metastatic breast cancer types shown to be responsive to carboplatin
e.g. triple negative disease, BRCA mutation carrier

Drug / Dosage:	Carboplatin AUC 6	IV	Day 1
Administration:	Carboplatin in 250 ml 5% glucose over 30 - 60 minutes		
Frequency:	3 weekly cycle for 6 cycles		
Main Toxicities:	myelosuppression; infertility/ovarian failure		
Anti- emetics:	highly emetogenic		
Extravasation:	non-vesicant		
Regular Investigations:	FBC	Day 1	
	U&Es	Day 1	
	LFTs	Day 1	
	EDTA	Prior to 1 st cycle	
	CA 15-3	Cycles 1, 3 & 5	

Comments: Carboplatin dose should be calculated using the Calvert Formula:
Dose = Target AUC x (25 + GFR)

Cycle 1 may be given using the Cockcroft and Gault (C&G) formula to predict creatinine clearance if the EDTA is not yet available. When using C&G, a “cap” of 125 ml/min should be used for carboplatin dose calculations.

Carboplatin dose should be re-calculated using the EDTA result for subsequent cycles (do not “cap”). EDTA should only be repeated if there is a 30% change in serum creatinine.

Dose Modifications

Haematological Toxicity:	Neutrophils < 1.5 x 10 ⁹ /l or Platelets < 75 x 10 ⁹ /l	Delay treatment for 1 week. Repeat FBC and, if normal, proceed with treatment, including dose reduction as below:
--------------------------	---	---

A dose reduction to AUC5 for subsequent cycles should be given for the following reasons:

- febrile neutropenia
- neutrophil count < 0.5 x 10⁹/l
- dose delay for haematological toxicity on two separate occasions
- platelet count < 50 x 10⁹/l
- day 21 neutrophil count < 1 x 10⁹/L with platelet count < 75 x 10⁹/l
- grade 2 peripheral neuropathy

Renal Impairment: Carboplatin is contra-indicated if GFR < 20 ml/min

Reason for Update: New - repeated off-protocol use	Approved by Consultant: Dr S Houston
Version: 1	Approved by Lead Chemotherapy Nurse: P Deery
Supersedes: None	Date: 12.5.15
Prepared by: S Taylor	Checked by: C Tucker

References:

Leong, CO et al; J Clin Invest 2007; 117 (5): 1370 – 1380
Dosing advice in line with the TNT study, NCRI, Version 5, 2013

Reason for Update: New - repeated off-protocol use	Approved by Consultant: Dr S Houston
Version: 1	Approved by Lead Chemotherapy Nurse: P Deery
Supersedes: None	Date: 12.5.15
Prepared by: S Taylor	Checked by: C Tucker